Royalty Pharma Plc Cash Flow-to-Debt Ratio
Royalty Pharma Plc cash flow-to-debt ratio. Royalty Pharma Plc (RPRX) has a Cash Flow-to-Debt Ratio of 0.08x as of March 2026, meaning its operating cash flow of $760.54 Million could theoretically repay 0% of its total liabilities ($9.88 Billion) in one year. Check RPRX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Royalty Pharma Plc (2002–2025)
Cash flow-to-debt ratio of Royalty Pharma Plc from 2002 to 2025. Historical debt coverage capacity for Royalty Pharma Plc across 14 annual periods. Check how aggressively does Royalty Pharma Plc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Royalty Pharma Plc Cash Flow-to-Debt Ratio by Year (2002–2025)
Royalty Pharma Plc cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Royalty Pharma Plc. For the full cash flow conversion analysis, see cash flow conversion of Royalty Pharma Plc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | $2.49 Billion | $9.91 Billion | ▼ -28.5% |
| 2024 | 0.35x | $2.77 Billion | $7.88 Billion | ▼ -25.9% |
| 2023 | 0.47x | $2.99 Billion | $6.30 Billion | ▲ +61.3% |
| 2022 | 0.29x | $2.14 Billion | $7.29 Billion | ▲ +6.0% |
| 2021 | 0.28x | $2.02 Billion | $7.27 Billion | ▼ -16.4% |
| 2020 | 0.33x | $2.03 Billion | $6.12 Billion | ▲ +25.7% |
| 2019 | 0.26x | $1.67 Billion | $6.31 Billion | ▲ +11.3% |
| 2018 | 0.24x | $1.62 Billion | $6.82 Billion | ▲ +15.5% |
| 2017 | 0.21x | $1.42 Billion | $6.90 Billion | ▲ +8039.6% |
| 2016 | 0.00x | $-15.58 Million | $6.02 Billion | ▲ +37.5% |
| 2015 | 0.00x | $-25.33 Million | $6.12 Billion | ▲ +100.0% |
| 2014 | -10.03x | $-29.33 Million | $2.92 Million | ▼ -148.7% |
| 2003 | 20.61x | $11.15 Million | $541.00K | ▲ +26.7% |
| 2002 | 16.27x | $8.45 Million | $519.00K | — |